Budesonide/Formoterol for Maintenance and Reliever Therapy Among Asthma Patients in Thailand

This study is not yet open for participant recruitment.

Verified by AstraZeneca, December 2008

Sponsored by:	AstraZeneca
Information provided by:	AstraZeneca
ClinicalTrials.gov Identifier:	NCT00800241

Purpose

The purpose of this study is to determine the incidence of misuse, i.e., over-use and under-use, of Budesonide/formoterol for maintenance and reliever therapy in usual-care setting.

Condition
Persistent Asthma

MedlinePlus related topics: Asthma

Drug Information available for: Formoterol Arformoterol Arformoterol Tartrate Formoterol fumarate Budesonide Symbicort

U.S. FDA Resources

Study Type:	Observational
Study Design:	Retrospective
Official Title:	Budesonide/Formoterol for Maintenance and Reliever Therapy: A Medication Use Evaluation Among Persistent Asthma Patients in General Practice in Thailand

Further study details as provided by AstraZeneca:

Primary Outcome Measures:

Thai asthma control test [ Time Frame: On the survey date ] [ Designated as safety issue: No ]

Biospecimen Retention: None Retained

Biospecimen Description:

Estimated Enrollment:	1020
Study Start Date:	December 2008
Estimated Study Completion Date:	March 2009

Eligibility

Ages Eligible for Study:	18 Years to 60 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No
Sampling Method:	Non-Probability Sample

Study Population

Patient aged 18-60 years old who established persistent asthma and currently treated with Symbicort SMART for 3 months or longer.

Criteria

Inclusion Criteria:

Established persistent asthma
Currently treated with Symbicort SMART for 3 months or longer

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00800241

Contacts

Contact: AstraZeneca Thailand Clinical study Information

66-2-7397400

thanu.komolsai@astrazeneca.com

Sponsors and Collaborators

AstraZeneca

Investigators

Principal Investigator:	Bandit Thinkhamrop, PhD.	Department of Biostatistics and Demography, Faculty of Public Health, Khon Kaen University
Principal Investigator:	Watchara Boonsawat, MD, PhD	Department of Medicine, Faculty of Medicine, Khon Kaen University

More Information

Responsible Party:	AstraZeneca (Thailand) Ltd. ( Thanu Komolsai, MD, Medical Advisor )
Study ID Numbers:	NIS-RTH-SYM-2008/1
Study First Received:	December 1, 2008
Last Updated:	December 1, 2008
ClinicalTrials.gov Identifier:	NCT00800241
Health Authority:	Thailand: Ethical Committee

Keywords provided by AstraZeneca:

Asthma
Symbicort SMART
Thai patient eligibility

Study placed in the following topic categories:

Hypersensitivity
Lung Diseases, Obstructive
Symbicort
Respiratory Tract Diseases
Lung Diseases

Budesonide
Hypersensitivity, Immediate
Formoterol
Asthma
Respiratory Hypersensitivity

Additional relevant MeSH terms:

Respiratory System Agents
Immune System Diseases
Bronchial Diseases

Therapeutic Uses
Anti-Asthmatic Agents
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 16, 2009